Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2026
Reporting Period: Quarter ended March 31, 2026
This filing serves as a notification of the Company's financial results for the first quarter of fiscal year 2026. The report incorporates by reference a press release (Exhibit 99.1) and a Supplemental Earnings Presentation (Exhibit 99.2) posted to the Company's Investor Relations website.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text provided does not contain specific numerical values for revenue, net income, operating cash flow, profit margins, debt levels, or liquidity ratios. These figures are contained within the referenced exhibits (Exhibit 99.1 and Exhibit 99.2) which are not included in the source text.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. Investors must refer to the attached press release and supplemental presentation for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing references the existence of a Supplemental Earnings Presentation which typically contains management commentary and forward-looking guidance, but the text of this 8-K does not summarize specific outlook figures or strategic updates.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the body of this filing. The document notes that the information in the exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements contained therein.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue and earnings per share figures.
- Access Exhibit 99.2 (Supplemental Earnings Presentation) for detailed segment performance, margin analysis, and full-year guidance.
- Verify the forward-looking statements disclaimer in the exhibits to understand the limitations on the provided outlook.
- Confirm the quarter-end date of March 31, 2026, aligns with the Company's fiscal calendar for accurate period comparison.